Explore Alterity Therapeutics' February 2025 Form 6-K filing, detailing its development stage, annual reporting plans, and securities offerings. Key insights and compliance updates included.
Explore the latest Form 6-K report from Alterity Therapeutics, detailing ownership changes, regulatory compliance, and the company's development stage focus.
Alterity Therapeutics Limited's Form 6-K reveals critical SEC disclosures, annual report plans, and security applications as of February 2025.
Explore Alterity Therapeutics Limited's regulatory compliance report for February 2025, detailing filing status, annual report compliance, and key exhibits.
Discover Alterity Therapeutics Limited's latest SEC Form 6-K, detailing A$40M raised for ATH434's development targeting Multiple System Atrophy (MSA).
Explore Alterity Therapeutics Limited's February 2025 Form 6-K detailing compliance, securities issuance, and growth strategies for investors.
Explore Alterity Therapeutics' latest Form 6-K report, detailing regulatory compliance, director interest changes, and insights for investors. Stay informed on governance and market focus.
Explore Alterity Therapeutics Limited's December 2024 Form 6-K filing, detailing regulatory compliance, exhibits, and key financial disclosures for investors.